Product Code: GVR-4-68039-394-2
miRNA Sequencing And Assay Market Growth & Trends:
The global miRNA sequencing and assay market size is expected to reach USD 823.5 Million by 2030, registering a CAGR of 13.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. For instance, various research studies stated that miRNAs can be efficiently used as biomarkers in the prognosis and diagnosis of cancer (cervical, ovarian, and breast), sepsis, cardiovascular diseases, and nervous system conditions. Thus, miRNA sequence analysis is significantly employed for gene regulation analysis in clinical disorders. For instance, an article published in frontiers, in March 2022, stated that blood-based miRNA biomarkers could be used to correlate brain-based miRNA expression.
The COVID-19 pandemic has enhanced the usage of miRNA to identify the presence of coronavirus. miRNA biomarkers have potential application to indicate and diagnose the COVID-19 severity. It plays a significant role in immune response, viral proliferation, replication of infected cells, and cardiovascular dysfunction. In addition, plasma recovered from COVID-19 patients is rich in antibodies and antiviral miRNAs. It has been utilized to treat COVID-19-infected patients. This has resulted in increasing research studies that focus on the miRNA sequence analysis from the patient as well as the virus.
Prominent players such as PerkinElmer Inc.; Illumina, Inc.; and Qiagen offer innovative sequencing products for several clinical applications. Furthermore, these companies have entered into several strategic initiatives with research institutes to expand the sequencing application in research studies. For instance, in January 2022, BIORCHESTRA, a South Korean biopharmaceutical company, entered into a partnership agreement with SK Biopharmaceuticals to accelerate research and development into novel therapeutic compounds that target miRNAs.
Key market players are involved in the development of new tools, instruments, and kits with high specificity and reproducibility, which is fueling the market growth. For instance, in October 2019, TriLink BioTechnologies introduced two primer sets for its CleanTag kit. Thermo Fisher Scientific's sequencer platform can prepare small RNA libraries using these new Ion Torrent Convert barcode primer sets. Such launches are expected to boost market growth.
miRNA Sequencing And Assay Market Report Highlights:
- The products segment dominated the market with the largest revenue share of around 80% in 2022. This is due to the presence of several key companies that offer a broad range of consumables, kits, and instruments for specific applications
- By technology, the sequencing by synthesis segment dominated the market with the largest revenue share of over 32% in 2022. This is due to its fast turnaround time, high sensitivity, and high throughput. Moreover, it plays a key role in the mutation detection of tumor tissue, which helps to develop personalized therapies
- By workflow, the sequencing segment dominated the market with the largest revenue share of over 50% in 2022 and is expected to grow at the fastest CAGR of 14.1% over the forecast period as it is the most important step in the workflow. It has become a key research tool in biological research and several disease diagnoses
- By application, the cancer segment dominated the market and accounted for the largest revenue share of over 35% in 2022. Several ongoing research in cancer using miRNA as a biomarker to study the prognosis and diagnosis of cancer to develop new therapies is contributing to the segment growth
- By end-use, the research and academic institutes segment dominated the market and accounted for the largest revenue share of over 50% in 2022. The growth is attributed to the increased R&D studies conducted by academic institutes using miRNA sequencing techniques
- Asia Pacific is expected to grow at the fastest CAGR of 15.4% during the forecast period. This is due to the growing healthcare infrastructure, significant targeted population, and high unmet clinical needs
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Product & Service
- 1.1.2. Technology
- 1.1.3. Workflow
- 1.1.4. Application
- 1.1.5. End use
- 1.1.6. Regional scope
- 1.1.7. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product & service outlook
- 2.2.2. Technology outlook
- 2.2.3. Workflow outlook
- 2.2.4. Application outlook
- 2.2.5. End use outlook
- 2.2.6. Regional outlook
- 2.3. Competitive Insights
Chapter 3. miRNA Sequencing And Assay Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. miRNA Sequencing And Assay Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. miRNA Sequencing And Assay: Product & Service Estimates & Trend Analysis
- 4.1. miRNA Sequencing And Assay Market: Key Takeaways
- 4.2. miRNA Sequencing And Assay Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Products
- 4.3.1. Products market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.2. Library preparation kits
- 4.3.2.1. Library preparation kits market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.3. Sequencing consumables
- 4.3.3.1. Sequencing consumables market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.4. Instruments
- 4.3.4.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Services
- 4.4.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. MiRNA Sequencing And Assay: Technology Estimates & Trend Analysis
- 5.1. MiRNA Sequencing And Assay Market: Key Takeaways
- 5.2. MiRNA Sequencing And Assay Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Sequencing by synthesis
- 5.3.1. Sequencing by synthesis market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Sequencing By Oligonucleotide Ligation and Detection (SOLiD)
- 5.4.1. Sequencing by oligonucleotide ligation and detection (SOLiD) market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Nanopore Sequencing
- 5.5.1. Nanopore sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Sanger Sequencing
- 5.6.1. Sanger sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Single molecule real - time (SMRT) Sequencing
- 5.7.1. Single molecule real - time (SMRT) sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. MiRNA Sequencing And Assay: Workflow Estimates & Trend Analysis
- 6.1. MiRNA Sequencing And Assay Market: Key Takeaways
- 6.2. MiRNA Sequencing And Assay Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Library Preparation
- 6.3.1. Library preparation market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Sequencing
- 6.4.1. Sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Data analysis & storage
- 6.5.1. Data analysis & storage market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. MiRNA Sequencing And Assay: Application Estimates & Trend Analysis
- 7.1. MiRNA Sequencing And Assay Market: Key Takeaways
- 7.2. MiRNA Sequencing And Assay Market: Movement & Market Share Analysis, 2022 & 2030
- 7.3. Cancer
- 7.3.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4. Polyglutamine Diseases
- 7.4.1. Polyglutamine diseases market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5. Autoimmune Disease
- 7.5.1. Autoimmune disease market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6. Schizophrenia
- 7.6.1. Schizophrenia market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7. Others
- 7.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. MiRNA Sequencing And Assay: End Use Estimates & Trend Analysis
- 8.1. MiRNA Sequencing And Assay Market: Key Takeaways
- 8.2. MiRNA Sequencing And Assay Market: Movement & Market Share Analysis, 2022 & 2030
- 8.3. Pharmaceutical & Biotechnology Industry
- 8.3.1. Pharmaceutical & biotechnology industry market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.4. Research & Academic Institutes
- 8.4.1. Research & academic institutes market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.5. Others
- 8.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. MiRNA Sequencing And Assay: Regional Estimates & Trend Analysis
- 9.1. Regional Outlook
- 9.2. MiRNA Sequencing And Assay Market by Region: Key Takeaway
- 9.3. North America
- 9.3.1. North America market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.3.2. U.S.
- 9.3.2.1. U.S. market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.3.3. Canada
- 9.3.3.1. Canada market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.4. Europe
- 9.4.1. Europe market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.4.2. UK
- 9.4.2.1. UK market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.4.3. Germany
- 9.4.3.1. Germany market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.4.4. France
- 9.4.4.1. France market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.4.5. Italy
- 9.4.5.1. Italy market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.4.6. Spain
- 9.4.6.1. Spain market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.4.7. Sweden
- 9.4.7.1. Sweden market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.4.8. Norway
- 9.4.8.1. Norway market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.4.9. Denmark
- 9.4.9.1. Denmark market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.5. Asia Pacific
- 9.5.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.5.2. Japan
- 9.5.2.1. Japan market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.5.3. China
- 9.5.3.1. China market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.5.4. India
- 9.5.4.1. India market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.5.5. Australia
- 9.5.5.1. Australia market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.5.6. Thailand
- 9.5.6.1. Thailand market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.5.7. South Korea
- 9.5.7.1. South Korea market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.6. Latin America
- 9.6.1. Latin America market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.6.2. Brazil
- 9.6.2.1. Brazil market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.6.3. Mexico
- 9.6.3.1. Mexico market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.6.4. Argentina
- 9.6.4.1. Argentina market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.7. MEA
- 9.7.1. MEA market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.7.2. Saudi Arabia
- 9.7.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.7.3. South Africa
- 9.7.3.1. South Africa market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.7.4. UAE
- 9.7.4.1. UAE market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
- 9.7.5. Kuwait
- 9.7.5.1. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
Chapter 10. Competitive Landscape
- 10.1. Recent Developments & Impact Analysis, By Key Market Participants
- 10.2. Market Participant Categorization
- 10.2.1. Thermo Fisher Scientific, Inc.
- 10.2.1.1. Company overview
- 10.2.1.2. Financial performance
- 10.2.1.3. Product benchmarking
- 10.2.1.4. Strategic initiatives
- 10.2.2. Illumina, Inc.
- 10.2.2.1. Company overview
- 10.2.2.2. Financial performance
- 10.2.2.3. Product benchmarking
- 10.2.2.4. Strategic initiatives
- 10.2.3. QIAGEN
- 10.2.3.1. Company overview
- 10.2.3.2. Financial performance
- 10.2.3.3. Product benchmarking
- 10.2.3.4. Strategic initiatives
- 10.2.4. PerkinElmer, Inc
- 10.2.4.1. Company overview
- 10.2.4.2. Financial performance
- 10.2.4.3. Product benchmarking
- 10.2.4.4. Strategic initiatives
- 10.2.5. Abcam plc
- 10.2.5.1. Company overview
- 10.2.5.2. Financial performance
- 10.2.5.3. Product benchmarking
- 10.2.5.4. Strategic initiatives
- 10.2.6. New England Biolabs
- 10.2.6.1. Company overview
- 10.2.6.2. Financial performance
- 10.2.6.3. Product benchmarking
- 10.2.6.4. Strategic initiatives
- 10.2.7. Takara Bio Inc.
- 10.2.7.1. Company overview
- 10.2.7.2. Financial performance
- 10.2.7.3. Product benchmarking
- 10.2.7.4. Strategic initiatives
- 10.2.8. Lexogen GmbH
- 10.2.8.1. Company overview
- 10.2.8.2. Financial performance
- 10.2.8.3. Product benchmarking
- 10.2.8.4. Strategic initiatives
- 10.2.9. Norgen Biotek Corp.
- 10.2.9.1. Company overview
- 10.2.9.2. Financial performance
- 10.2.9.3. Product benchmarking
- 10.2.9.4. Strategic initiatives
- 10.2.10. Maravai LifeSciences
- 10.2.10.1. Company overview
- 10.2.10.2. Financial performance
- 10.2.10.3. Product benchmarking
- 10.2.10.4. Strategic initiatives
- 10.2.11. HTG Molecular Diagnostics, Inc.
- 10.2.11.1. Company overview
- 10.2.11.2. Financial performance
- 10.2.11.3. Product benchmarking
- 10.2.11.4. Strategic initiatives
- 10.2.12. Meridian Bioscience, Inc.
- 10.2.12.1. Company overview
- 10.2.12.2. Financial performance
- 10.2.12.3. Product benchmarking
- 10.2.12.4. Strategic initiatives
- 10.2.13. System Biosciences, LLC
- 10.2.13.1. Company overview
- 10.2.13.2. Financial performance
- 10.2.13.3. Product benchmarking
- 10.2.13.4. Strategic initiatives